MX2020011591A - Usos de antagonistas de iap en infecciones intracelulares. - Google Patents
Usos de antagonistas de iap en infecciones intracelulares.Info
- Publication number
- MX2020011591A MX2020011591A MX2020011591A MX2020011591A MX2020011591A MX 2020011591 A MX2020011591 A MX 2020011591A MX 2020011591 A MX2020011591 A MX 2020011591A MX 2020011591 A MX2020011591 A MX 2020011591A MX 2020011591 A MX2020011591 A MX 2020011591A
- Authority
- MX
- Mexico
- Prior art keywords
- intracellular infection
- treating intracellular
- treating
- subject
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
Abstract
La presente invención proporciona un método para tratar una infección intracelular en un sujeto, en donde el método comprende administrar al sujeto un antagonista de IAP. En ciertas modalidades, el antagonista de IAP es un mimético de Smac.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013902327A AU2013902327A0 (en) | 2013-06-25 | Method of treating intracellular infection | |
AU2014901029A AU2014901029A0 (en) | 2014-03-24 | Method of treating intracellular infection | |
AU2014901977A AU2014901977A0 (en) | 2014-05-26 | Method of treating intracellular infection |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011591A true MX2020011591A (es) | 2020-12-07 |
Family
ID=52140681
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016628A MX2015016628A (es) | 2013-06-25 | 2014-06-25 | Metodo para tratar infeccion intracelular. |
MX2020011591A MX2020011591A (es) | 2013-06-25 | 2015-12-02 | Usos de antagonistas de iap en infecciones intracelulares. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016628A MX2015016628A (es) | 2013-06-25 | 2014-06-25 | Metodo para tratar infeccion intracelular. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10500252B2 (es) |
EP (2) | EP3682873B1 (es) |
JP (2) | JP6785653B2 (es) |
KR (3) | KR20200108904A (es) |
CN (3) | CN111481669A (es) |
AU (1) | AU2014301958B2 (es) |
CA (1) | CA2913189C (es) |
EA (1) | EA036275B1 (es) |
ES (1) | ES2828642T3 (es) |
HK (1) | HK1224230A1 (es) |
IL (1) | IL242678B (es) |
MX (2) | MX2015016628A (es) |
NZ (2) | NZ714347A (es) |
SG (1) | SG11201509525XA (es) |
WO (1) | WO2014205516A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
CN106265764B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
CN108440507B (zh) * | 2017-02-16 | 2022-10-18 | 南京圣和药物研发有限公司 | 作为细胞凋亡蛋白抑制剂的化合物及其应用 |
CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
JP7414981B2 (ja) * | 2020-12-28 | 2024-01-16 | 中以海▲徳▼人工智能▲薬▼物研▲発▼股▲ふん▼有限公司 | ウイルス性肝炎を治療又は予防するための薬物組成物及びその応用 |
CN112933085B (zh) * | 2020-12-28 | 2021-12-21 | 中以海德人工智能药物研发股份有限公司 | 一种化合物在制备治疗或预防病毒性肝炎用药物中的应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
ES2253753T3 (es) | 1995-06-29 | 2006-06-01 | Immunex Corporation | Citocina que induce apoptosis. |
US5705109A (en) | 1996-06-20 | 1998-01-06 | Westvaco Corporation | Ozone treatment for composite paperboard/polymer package |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
BRPI9908967B1 (pt) | 1998-03-20 | 2017-05-30 | Benitec Australia Ltd | processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta |
CA2325344C (en) | 1998-04-08 | 2017-12-05 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
EP1317288A2 (en) | 2000-09-11 | 2003-06-11 | MUSC Foundation For Research Development | Method and composition for treating tumors by selective induction of apoptosis |
US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
US20040138119A1 (en) * | 2002-09-18 | 2004-07-15 | Ingo Tamm | Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
JP2007522116A (ja) | 2004-01-16 | 2007-08-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | コンホメーションが制約されたSmac模倣物およびその使用 |
US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
EP2253614B1 (en) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
US7244851B2 (en) | 2004-07-02 | 2007-07-17 | Genentech, Inc. | Inhibitors of IAP |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
EP1851200B1 (en) | 2005-02-25 | 2014-01-15 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
MX2007015419A (es) | 2005-06-08 | 2008-02-21 | Novartis Ag | Compuestos organicos. |
AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
JP5227805B2 (ja) | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Iap阻害剤とタキサン7の組合せ剤 |
CN101484151B (zh) * | 2006-05-05 | 2012-11-21 | 密执安州立大学董事会 | 二价smac模拟物及其应用 |
PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
CA2670498A1 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Combination of iap inhibitors and flt3 inhibitors |
WO2008124129A2 (en) * | 2007-04-09 | 2008-10-16 | University Of Massachusetts | Treating hiv with a m-csf effector kinase inhibitor like imatinib |
WO2009025743A2 (en) | 2007-08-17 | 2009-02-26 | University Of Massachusetts Medical School | Use of trail compositions as antiviral agents |
ES2882855T3 (es) * | 2008-05-16 | 2021-12-02 | Dana Farber Cancer Inst Inc | Inmunomodulación por inhibidores de IAP |
KR101150254B1 (ko) | 2008-12-26 | 2012-06-12 | 한미사이언스 주식회사 | 신규 중간체 및 이를 활용한 엔테카비르 제조방법 |
CN102458417B (zh) * | 2009-06-24 | 2015-02-25 | 味之素株式会社 | 核酸类似物的活性增强剂 |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
ES2625637T3 (es) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | Compuestos de unión al dominio BIR IAP |
US8481728B2 (en) * | 2010-02-16 | 2013-07-09 | Scinopharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant)) |
US20140309265A1 (en) * | 2011-11-09 | 2014-10-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
US20140303090A1 (en) | 2013-04-08 | 2014-10-09 | Tetralogic Pharmaceuticals Corporation | Smac Mimetic Therapy |
US10300074B2 (en) * | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
-
2014
- 2014-06-25 AU AU2014301958A patent/AU2014301958B2/en active Active
- 2014-06-25 ES ES14818270T patent/ES2828642T3/es active Active
- 2014-06-25 KR KR1020207024689A patent/KR20200108904A/ko not_active Application Discontinuation
- 2014-06-25 CN CN202010321579.7A patent/CN111481669A/zh active Pending
- 2014-06-25 EP EP20154353.5A patent/EP3682873B1/en active Active
- 2014-06-25 SG SG11201509525XA patent/SG11201509525XA/en unknown
- 2014-06-25 EP EP14818270.2A patent/EP3013329B1/en active Active
- 2014-06-25 NZ NZ714347A patent/NZ714347A/en unknown
- 2014-06-25 KR KR1020207024688A patent/KR20200108903A/ko not_active Application Discontinuation
- 2014-06-25 MX MX2015016628A patent/MX2015016628A/es unknown
- 2014-06-25 WO PCT/AU2014/050092 patent/WO2014205516A1/en active Application Filing
- 2014-06-25 CN CN201480036777.1A patent/CN105451726B/zh active Active
- 2014-06-25 JP JP2016522137A patent/JP6785653B2/ja active Active
- 2014-06-25 CA CA2913189A patent/CA2913189C/en active Active
- 2014-06-25 US US14/899,581 patent/US10500252B2/en active Active
- 2014-06-25 EA EA201690075A patent/EA036275B1/ru not_active IP Right Cessation
- 2014-06-25 NZ NZ754814A patent/NZ754814A/en unknown
- 2014-06-25 CN CN202110198940.6A patent/CN112957365A/zh active Pending
- 2014-06-25 KR KR1020157035155A patent/KR20160030099A/ko not_active IP Right Cessation
-
2015
- 2015-11-19 IL IL242678A patent/IL242678B/en unknown
- 2015-12-02 MX MX2020011591A patent/MX2020011591A/es unknown
-
2016
- 2016-11-04 HK HK16112703.5A patent/HK1224230A1/zh unknown
-
2019
- 2019-05-13 JP JP2019090712A patent/JP7203682B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3013329B1 (en) | 2020-08-05 |
ES2828642T3 (es) | 2021-05-27 |
KR20160030099A (ko) | 2016-03-16 |
NZ714347A (en) | 2020-01-31 |
CA2913189C (en) | 2020-08-25 |
MX2015016628A (es) | 2016-06-29 |
CN105451726A (zh) | 2016-03-30 |
SG11201509525XA (en) | 2016-01-28 |
AU2014301958A1 (en) | 2015-12-10 |
US20160143995A1 (en) | 2016-05-26 |
EP3013329A1 (en) | 2016-05-04 |
IL242678B (en) | 2021-08-31 |
KR20200108903A (ko) | 2020-09-21 |
CN105451726B (zh) | 2021-03-16 |
US10500252B2 (en) | 2019-12-10 |
AU2014301958B2 (en) | 2017-11-16 |
CN112957365A (zh) | 2021-06-15 |
EP3682873B1 (en) | 2024-06-12 |
EA036275B1 (ru) | 2020-10-21 |
EA201690075A1 (ru) | 2016-05-31 |
JP6785653B2 (ja) | 2020-11-18 |
CN111481669A (zh) | 2020-08-04 |
EP3013329A4 (en) | 2017-05-31 |
HK1224230A1 (zh) | 2017-08-18 |
JP7203682B2 (ja) | 2023-01-13 |
JP2019147823A (ja) | 2019-09-05 |
WO2014205516A1 (en) | 2014-12-31 |
CA2913189A1 (en) | 2014-12-31 |
JP2016523261A (ja) | 2016-08-08 |
KR20200108904A (ko) | 2020-09-21 |
NZ754814A (en) | 2021-07-30 |
EP3682873A1 (en) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011591A (es) | Usos de antagonistas de iap en infecciones intracelulares. | |
TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
EP2971635A4 (en) | ACTIVE SCAN PRE-CHAMBER | |
EP3089502A4 (en) | METHOD AND SYSTEM FOR EVALUATING USER PERCEPTIONS | |
EP3058394A4 (en) | Multifrequency processing to determine formation properties | |
HK1223608A1 (zh) | 嗎泛和嗎啡喃類似物和其用途 | |
PH12016500598A1 (en) | Protoxin-ii variants and methods of use | |
PT2957064T (pt) | Processo de prova de preservação da privacidade da fiabilidade entre três partes em comunicação | |
EP3692957C0 (en) | COMPRESSION GARMENT TO WICK AWAY SWEAT | |
SG10201705899XA (en) | Prevention & treatment of neuropathy | |
HK1217272A1 (zh) | 服裝部件、包含該服裝部件的服裝及其製造方法 | |
MX368870B (es) | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. | |
MX360704B (es) | Guante ambidiestro con textura de escama de pescado. | |
ZA201603463B (en) | An inhalable medicament | |
IN2013MU03216A (es) | ||
EP3060077A4 (en) | Apparel with discreet pocket | |
SI2843094T1 (sl) | Hlače za zaščito pred motorno žago | |
ZA201603464B (en) | An inhalable medicament | |
EP3019995A4 (en) | IDENTIFICATION OF ABUSE OF LEGITIMATE OBJECTS | |
EP3007721A4 (en) | BIOCONJUGATES OF MIMETIC COMPOUNDS OF AMYLINE AND POLYETHYLENE GLYCOL DO NOT AGGLOMERATE | |
TWM475395U (en) | Active detection protective clothing | |
EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
AU347914S (en) | Round shoulder cape | |
AU2013904138A0 (en) | Apparel with discreet pocket | |
TH1401007825A (th) | องค์ประกอบที่มีน้ำชาสำหรับการป้องกันการเปลี่ยนตามวัยของผิวหนัง |